Steven David, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared on X:
“Pleased to share our AZTEC RCT of SABR plus IO in advanced TNBC (TROG 17.05) out now in Nature Communications!
- Overall: Negative primary endpoint
- Positives: Safe, promising oligometastatic signals
- Translational: Biomarker insights to guide future trials.”
Title: Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
Authors: Steven David, Peter Savas, Shankar Siva, Mathias Bressel, Michelle White, Bronte Nikolic, Michael W. Neeson, Shane White, Gavin Marx, Robyn Cheuk, Michelle Grogan, Maria Farrell, Jessica Foudoulis, Paul J. Neeson, Sherene Loi.
Read the full article.
To which Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, added:
“Proud of Steven David and Trans Tasman Radiation Oncology Group team for n=54 randomised Ph II trial of SABR with atezolizumab immunotherapy in triple negative breast cancer. In-depth translational analysis here: Nature Communications. Higher CD8 TPEX cells tracked with longer response.”
